Re-expression of ER in Triple Negative Breast Cancers

This study has been terminated.
(Slow accrual)
Sponsor:
Collaborators:
Novartis
Eisai Inc.
Information provided by (Responsible Party):
Ruth O'Regan, Emory University
ClinicalTrials.gov Identifier:
NCT01194908
First received: September 1, 2010
Last updated: August 29, 2014
Last verified: August 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: January 2014
  Primary Completion Date: January 2014 (Final data collection date for primary outcome measure)